Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) has completed its legal name change from Cybin Inc. to Helus Pharma Inc., effective Oct. 1, 2026, following shareholder approval at the company's Sept. 22 annual and special meeting. The move formalizes the Helus Pharma business name adopted in January and underscores the company's anticipated transition from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company. Shares will continue trading under the ticker HELP on the Nasdaq Global Market and Cboe Canada, with no action required by existing shareholders.
The name change is more than cosmetic. It reflects Helus Pharma's growing focus on proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These investigational therapies target large unmet needs in depression, anxiety, and other mental health conditions. The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Another candidate, HLP004, is in Phase 2 for generalized anxiety disorder. Helus Pharma also maintains an extensive research portfolio of investigational NSAs and operates in Canada, the United States, the United Kingdom, and Ireland.
For investors and industry observers, the rebranding signals confidence in a pipeline that could disrupt the mental health treatment landscape. If approved, NSAs could offer durable improvements where existing therapies often fall short. The company's class-leading data and late-stage assets position it as a potential commercial player in a space that has seen renewed interest from both big pharma and investors. More details are available in the full press release at https://ibn.fm/rrJFh. For company updates, visit www.helus.com.
The announcement was disseminated through Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) and may include paid advertising. MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance visibility. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
The name change comes at a pivotal time for Helus Pharma as it seeks to transition from a research-focused entity to a commercial-stage company. With late-stage clinical trials underway and Breakthrough Therapy Designation in hand, the company aims to bring new hope to patients suffering from depression and anxiety. For the industry, it highlights the maturing psychedelic-inspired therapeutics sector and the potential for novel mechanisms to address mental health disorders. Investors will be watching closely as Helus Pharma advances its pipeline and prepares for potential regulatory milestones.
